BERLIN, June 13, 2008 (PRIME NEWSWIRE) -- aap bio implants group, the medical biomaterials division of aap Implantate AG has received CE approval for the new orthopaedic bone cement Hi-Fatigue(r) G (containing the antibiotic Gentamycin). For the product family Hi-Fatigue(r) an exclusive distribution agreement was signed with Zimmer. The product will be launched in European markets by Zimmer, the global leader in reconstructive orthopaedic implants within the coming months.
aap Implantate AG is a medical technology company quoted in the prime standard of the Frankfurt Stock Exchange.
aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated market - All German stock exchanges
aap is a medical technology company that develops, manufactures and markets bio-materials and implants for trauma and orthopaedics. Its product portfolio includes bone cements, bone graft substitutes, antibiotic carriers, and implants for fracture healing and joint replacement. In addition to its Berlin headquarters the company has locations in Dieburg and Obernburg near Frankfurt am Main, Dusseldorf as well as at Nijmegen in the Netherlands. aap Implantate AG has been listed in the Prime Standard segment at the Frankfurt stock exchange since May 16, 2003.
Please address any queries to: aap Implantate AG, Nanette Hudepohl, Head of Corporate Communications, Lorenzweg 5, 12099 Berlin, Germany Tel.: +49 30 7501 9133; Fax: +49 30 7501 9290; n.huedepohl@aap.de
For further information about aap bio implants, visit www.aap-bioimplants.com